Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -913.47 Thousand USD | 48.31% |
| 2021 | -1.75 Million USD | 27.46% |
| 2020 | -2.47 Million USD | -254.55% |
| 2019 | -734.1 Thousand USD | -40.04% |
| 2018 | -795.72 Thousand USD | 64.23% |
| 2017 | -1.25 Million USD | -62.94% |
| 2016 | -1.01 Million USD | 22.25% |
| 2015 | -694.74 Thousand USD | -4716.5% |
| 2014 | -979.62 Thousand USD | -68.62% |
| 2013 | -14.55 Thousand USD | -4.33% |
| 2012 | -13.9 Thousand USD | 19.81% |
| 2011 | -17.34 Thousand USD | 26.3% |
| 2010 | -23.52 Thousand USD | -46.86% |
| 2009 | -16.02 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | -276.41 Thousand USD | -2.51% |
| 2022 Q1 | -269.65 Thousand USD | 34.01% |
| 2022 Q4 | -157.36 Thousand USD | 45.87% |
| 2022 Q3 | -290.71 Thousand USD | -5.17% |
| 2022 FY | - USD | 48.31% |
| 2021 Q2 | -294 Thousand USD | -15.64% |
| 2021 FY | - USD | 27.46% |
| 2021 Q4 | -408.61 Thousand USD | 57.71% |
| 2021 Q3 | -966.25 Thousand USD | -228.65% |
| 2021 Q1 | -254.25 Thousand USD | 84.83% |
| 2020 Q1 | -207.63 Thousand USD | 7.44% |
| 2020 Q2 | -316.21 Thousand USD | -52.29% |
| 2020 Q3 | -451.12 Thousand USD | -42.66% |
| 2020 Q4 | -1.67 Million USD | -271.52% |
| 2020 FY | - USD | -254.55% |
| 2019 Q1 | -214.12 Thousand USD | -34.81% |
| 2019 Q2 | -150.72 Thousand USD | 29.61% |
| 2019 Q3 | -158.52 Thousand USD | -5.17% |
| 2019 Q4 | -224.32 Thousand USD | -41.51% |
| 2019 FY | - USD | -40.04% |
| 2018 FY | - USD | 64.23% |
| 2018 Q4 | -158.82 Thousand USD | -1059.25% |
| 2018 Q1 | -184.53 Thousand USD | 63.03% |
| 2018 Q2 | -176.83 Thousand USD | 4.17% |
| 2018 Q3 | -13.7 Thousand USD | 92.25% |
| 2017 FY | - USD | -62.94% |
| 2017 Q4 | -499.13 Thousand USD | -82.96% |
| 2017 Q3 | -272.8 Thousand USD | -22.77% |
| 2017 Q2 | -222.21 Thousand USD | 55.99% |
| 2017 Q1 | -504.93 Thousand USD | -23.06% |
| 2016 FY | - USD | 22.25% |
| 2016 Q1 | -140.62 Thousand USD | 88.07% |
| 2016 Q2 | -177.66 Thousand USD | -26.33% |
| 2016 Q3 | -187.41 Thousand USD | -5.49% |
| 2016 Q4 | -410.3 Thousand USD | -118.93% |
| 2015 Q1 | -7531.00 USD | -44.83% |
| 2015 Q2 | -7432.00 USD | 1.31% |
| 2015 Q3 | -12.31 Thousand USD | -65.66% |
| 2015 FY | - USD | -4716.5% |
| 2015 Q4 | -1.17 Million USD | -9476.42% |
| 2014 FY | - USD | -68.62% |
| 2014 Q2 | -8975.00 USD | -704.93% |
| 2014 Q4 | -5200.00 USD | 43.31% |
| 2014 Q1 | -1115.00 USD | 50.47% |
| 2014 Q3 | -9172.00 USD | -2.19% |
| 2013 Q2 | -7667.00 USD | -224.46% |
| 2013 Q1 | -2363.00 USD | 14.32% |
| 2013 Q3 | -2274.00 USD | 70.34% |
| 2013 Q4 | -2251.00 USD | 1.01% |
| 2013 FY | - USD | -4.33% |
| 2012 FY | - USD | 19.81% |
| 2012 Q4 | -2758.00 USD | -27.33% |
| 2012 Q3 | -2166.00 USD | -21.89% |
| 2012 Q1 | -7418.00 USD | -260.45% |
| 2012 Q2 | -1777.00 USD | 76.04% |
| 2011 Q1 | -7244.00 USD | 38.32% |
| 2011 Q3 | -6120.00 USD | -218.92% |
| 2011 Q2 | -1919.00 USD | 73.51% |
| 2011 FY | - USD | 26.3% |
| 2011 Q4 | -2058.00 USD | 66.37% |
| 2010 FY | - USD | -46.86% |
| 2010 Q4 | -11.74 Thousand USD | -37.3% |
| 2010 Q1 | -483.00 USD | -34.54% |
| 2010 Q3 | -8554.00 USD | -211.51% |
| 2010 Q2 | -2746.00 USD | -468.53% |
| 2009 Q4 | -359.00 USD | -14.7% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | -313.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -104.223% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 96.904% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 99.199% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 94.204% |
| Better Therapeutics, Inc. | -38.26 Million USD | 97.613% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 97.613% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 94.893% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 97.292% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 97.263% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 99.141% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 97.188% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 98.044% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 83.928% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 94.396% |
| Molecular Templates, Inc. | 1.43 Million USD | 163.879% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 93.416% |
| NexImmune, Inc. | -28.16 Million USD | 96.757% |
| Orgenesis Inc. | -60.71 Million USD | 98.496% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 98.219% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -1144.242% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 94.342% |
| Scopus BioPharma Inc. | -11.71 Million USD | 92.201% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.831% |
| Statera Biopharma, Inc. | 38.93 Million USD | 102.346% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 86.73% |
| Trevena, Inc. | -35.28 Million USD | 97.411% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -1529.718% |
| Vaccinex, Inc. | -19.74 Million USD | 95.374% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 12.751% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 98.051% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 87.423% |